Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016)

被引:1
|
作者
Carvalhaes, Cecilia G. [1 ]
Huband, Michael D. [1 ]
Reinhart, Harald H. [2 ]
Flamm, Robert K. [1 ]
Sader, Helio S. [1 ]
机构
[1] JMI Labs, North Liberty, IA 52317 USA
[2] Zai Lab Shanghai Co Ltd, Shanghai, Peoples R China
关键词
Staphylococcus aureus; Streptococcus pneumoniae; aminomethylcycline; community-acquired pneumonia; skin and soft tissue infections; tetracyclines; RESISTANCE; EPIDEMIOLOGY;
D O I
10.1128/AAC.02262-18
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Omadacycline is a derivative of minocycline and the first agent of the aminomethylcycline class. A total of 3,282 organisms (1 per patient) were consecutively collected from patients hospitalized in China (including Hong Kong) and Taiwan. Susceptibility testing was performed by broth microdilution methods in a central laboratory (JMI Laboratories). The collection included Gram-positive and Gramnegative organisms from patients with pneumonia, bloodstream, skin, community-acquired respiratory, and other infections. Omadacycline was very potent against Staphylococcus aureus (n = 689; MIC50/90, 0.12/0.25 mg/liter), including methicillin-resistant Staphylococcus aureus (MRSA; n = 299; MIC50/90, 0.12/0.5 mg/liter), and had similar activity across geographic regions. Omadacycline was very active against Streptococcus pneumoniae (highest MIC, 0.25 mg/liter), beta-hemolytic streptococci (highest MIC, 1 mg/liter), viridans group streptococci (highest MIC, 0.25 mg/liter), and Enterococcus spp. (highest MIC, 0.5 mg/liter) from all geographic regions. Overall, 53.8% of S. pneumoniae isolates were penicillin resistant (penicillin MIC, >2 mg/liter) and 10.7% of enterococci (21.2% among E. faecium isolates) were vancomycin resistant. Omadacycline was active against Haemophilus influenzae (MIC50/90, 0.5/1 mg/liter) regardless of beta-lactamase production and was active against Moraxella catarrhalis (MIC50/90, <= 0.12/0.25 mg/liter). Against Enterobacteriaceae, omadacycline was most active against Escherichia coli (MIC50/90, 1/2 mg/liter), Klebsiella oxytoca (MIC50/90, 1/4 mg/liter), and Enterobacter cloacae (MIC50/90, 2/4 mg/liter). Omadacycline had potent in vitro activity against Gram-positive and Gram-negative pathogens isolated from China and Taiwan and retained activity against problem pathogens, such as MRSA, vancomycin-resistant enterococci (VRE), penicillin-resistant S. pneumoniae (PRSPN), and extended-spectrum beta-lactamase-producing E. coli. The observed MIC profile in Chinese isolates was very similar to that seen in the U.S. and European surveillance studies.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Ceftaroline Activity Tested Against Bacterial Isolates From Pediatric Patients Results from the Assessing Worldwide Antimicrobial Resistance and Evaluation Program for the United States (2011-2012)
    Sader, Helio S.
    Mendes, Rodrigo E.
    Farrell, David J.
    Flamm, Robert K.
    Jones, Ronald N.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2014, 33 (08) : 837 - 842
  • [42] Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and north America (2003): Initial results from an international surveillance protocol
    Jones, RN
    Fritsche, TR
    Sader, HS
    Goldstein, BP
    JOURNAL OF CHEMOTHERAPY, 2005, 17 (06) : 593 - 600
  • [43] Salmonella spp. isolates causing bloodstream infections in Latin America:: report of antimicrobial activity from the SENTRY Antimicrobial Surveillance Program (1997-2000)
    Gales, AC
    Sader, HS
    Mendes, RE
    Jones, RN
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2002, 44 (03) : 313 - 318
  • [44] ANTIMICROBIAL ACTIVITY OF 11 NEWER AND INVESTIGATIONAL DRUGS TESTED AGAINST AEROBIC ISOLATES FROM SPONTANEOUS BACTERIAL PERITONITIS
    SADER, HS
    RUNYON, BA
    ERWIN, ME
    JONES, RN
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1995, 21 (02) : 105 - 110
  • [45] Bacterial susceptibility in bloodstream infections: Results from China Antimicrobial Resistance Surveillance Trial (CARST) Program, 2015-2016
    Zhang, Fan
    Li, Yun
    Lv, Yuan
    Zheng, Bo
    Xue, Feng
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2019, 17 : 276 - 282
  • [46] Antimicrobial resistance of Haemophilus influenzae isolates from pediatric hospitals in Mainland China: Report from the ISPED program, 2017-2019
    Zhou, Mingming
    Fu, Pan
    Fang, Chao
    Shang, Shiqiang
    Hua, Chunzhen
    Jing, Chunmei
    Xu, Hongmei
    Chen, Yunsheng
    Deng, Jikui
    Zhang, Hong
    Zhang, Ting
    Wang, Shifu
    Lin, Aiwei
    Huang, Weichun
    Cao, Qing
    Wang, Chuanqing
    Yu, Hui
    Cao, Sancheng
    Deng, Huiling
    Gao, Wei
    Hao, Jianhua
    INDIAN JOURNAL OF MEDICAL MICROBIOLOGY, 2021, 39 (04) : 434 - 438
  • [47] Antimicrobial Activity of Doripenem Tested Against Leading Bacterial Pathogens: Results from a Latin American Surveillance Study (2003-2006)
    Gales, Ana C.
    Jones, Ronald N.
    Sader, Helio S.
    Fritsche, Thomas R.
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2008, 12 : 59 - 66
  • [48] Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009-2012
    Sader, Helio S.
    Farrell, David J.
    Flamm, Robert K.
    Jones, Ronald N.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2014, 43 (04) : 328 - 334
  • [49] Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000):: More alike than different!
    Jones, RN
    Beach, ML
    Pfaller, MA
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2001, 41 (03) : 161 - 163
  • [50] Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones:: prevalence results from the SENTRY antimicrobial surveillance program
    Biedenbach, DJ
    Jones, RN
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2003, 46 (01) : 55 - 61